Table 2. Multivariate analysis of clinicopathologic parameters for survival of patients with diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP.
| Overall survival | Progression-free survival | |||||
|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | |
| DLBCL (n = 497) | ||||||
| IPI > 2 | 2.41 | 1.70–3.42 | < 0.001 | 2.29 | 1.64–3.19 | < 0.001 |
| Female sex | 1.03 | 0.72–1.49 | 0.86 | 0.99 | 0.70–1.41 | 0.98 |
| Tumor size ≥ 5 cm | 1.28 | 0.91–1.81 | 0.16 | 1.23 | 0.89–1.71 | 0.21 |
| B-symptoms | 1.35 | 0.94–1.94 | 0.099 | 1.31 | 0.93–1.85 | 0.12 |
| p65high | 1.56 | 0.91–2.68 | 0.11 | 1.44 | 0.85–2.42 | 0.18 |
| GCB-DLBCL (n = 243) | ||||||
| IPI > 2 | 2.47 | 1.40–4.38 | 0.002 | 2.39 | 1.39–4.09 | 0.002 |
| Female sex | 1.00 | 0.55–1.82 | 1.00 | 0.98 | 0.56–1.71 | 0.95 |
| Tumor size ≥ 5 cm | 1.30 | 0.88–1.91 | 0.19 | 1.40 | 0.82–2.40 | 0.22 |
| B-symptoms | 1.44 | 0.80–2.58 | 0.22 | 1.34 | 0.77–2.33 | 0.31 |
| p65high | 2.30 | 1.14–4.62 | 0.02 | 2.01 | 1.06–3.82 | 0.034 |
| WT-TP53 DLBCL (n = 338) | ||||||
| IPI > 2 | 2.54 | 1.66–3.88 | < 0.001 | 2.33 | 1.57–3.46 | < 0.001 |
| Female sex | 0.98 | 0.63–1.53 | 0.92 | 0.99 | 0.65–1.51 | 0.96 |
| Tumor size ≥ 5 cm | 1.20 | 0.79–1.84 | 0.39 | 1.09 | 0.73–1.63 | 0.18 |
| B-symptoms | 1.59 | 1.04–2.43 | 0.034 | 1.57 | 1.05–2.33 | 0.028 |
| p65high | 1.91 | 1.04–3.52 | 0.037 | 1.94 | 1.08–3.48 | 0.026 |
Abbreviations: R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone; HR, hazard ratio; CI, confidence interval; IPI, International Prognostic Index; p65high, high levels of nuclear p65; GCB, germinal center B-cell–like; ABC, activated B-cell–like; WT-TP53, wild-type TP53. *Significant P values in bold.